Changes in Oral Anticoagulant Treatment Rates in Atrial Fibrillation before and after the Introduction of Direct Oral Anticoagulants

Abstract

<b><i>Background:</i></b> Direct oral anticoagulants (DOACs) have the potential to improve stroke prevention among atrial fibrillation (AF) patients. We sought to determine if oral anticoagulation (OAC) treatment rates have increased since the approval of DOACs. <b><i>Methods:</i></b> We identified 6,688 patients with AF at an academic medical center from January 2008 to June 2015. We examined OAC prescription rates over time and according to CHA<sub>2</sub>DS<sub>2</sub>VASc score using multivariable Poisson regression models, with an interaction term between risk score and year of AF diagnosis. <b><i>Results:</i></b> Among 6,688 AF patients, 78% had CHA<sub>2</sub>DS<sub>2</sub>VASc scores ≥2, 51.6% of whom received an OAC prescription within 90 days of diagnosis. The OAC prescription rate was 47.8% in the pre-DOAC era and peaked at 56.4% in 2014. Relative to the pre-DOAC era, prescription rates increased in 2012 and leveled off thereafter. The prescription rate for the highest risk group was 58.5%, compared with 45.0% in patients with a CHA<sub>2</sub>DS<sub>2</sub>VASc score of 2 (<i>p</i> < 0.01). In the adjusted analysis, prescription rates were higher for the higher risk group (adjusted relative risk 1.24 for CHA<sub>2</sub>DS<sub>2</sub>VASc score 7-9 vs. 2, 95% CI 1.09-1.40). <b><i>Conclusions:</i></b> OAC treatment rates have increased since DOAC introduction, but substantial treatment gaps remain, specifically among the higher risk patients.